Breaking News

Wolfe Labs Appoints Pharma Sciences VP

January 4, 2012

Casebier assumes responsibility for strategic R&D programs

David Casebier, Ph.D. has been named vice president of Pharmaceutical Sciences at Wolfe Laboratories. Dr. Casebier will be responsible for strategic programs in R&D, focusing specifically on the innovation and growth of Wolfe’s proprietary analytical and formulation technology platforms.

Most recently, Dr. Casebier served as senior vice president for Pharmaceutical Sciences at Tokai Pharmaceuticals, where he successfully oversaw the formulation, development, and manufacturing of a novel therapeutic for prostate cancer. Previously, he was senior director of chemistry at Lantheus Medical Imaging, formerly a division of Bristol-Meyers Squibb. While at BMS, he was responsible for all aspects of chemistry from project conception to commercial launch, including medicinal chemistry and API manufacturing.

“We are excited for David to join Wolfe’s team,” said Janet Wolfe, Ph.D., founder and president of Wolfe Laboratories. “His proven ability to form and lead technically innovative teams is particularly timely as demand for Wolfe’s services increases amongst large biopharmaceutical companies. As Wolfe expands its capabilities in the areas of complex small molecule dosage forms, biologics, biosimilars, and targeted therapeutics, David’s wealth of drug development experience will accelerate the flow of technical innovation through the pipelines of our clients.”
  • When Quality Meets Confidence

    When Quality Meets Confidence

    Dr. Fadia AlKhalil, Vice President of Global Business Development for Laboratory Services, SGS ||November 9, 2016
    A look at global account management for R&D outsourcing

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus